BridgeMD
MOTHER trial: Efficacy and safety of low-dose intrathecal morphine following planned caesarean section
EU CTIS ID: 2024-518678-16-00
What this study is testing
The aim of this trial is to evaluate analgesic efficacy and safety (patients and neonates) associated with addition of low-dose (80 µg) intrathecal morphine versus placebo to standard multimodal postoperative pain management in patients undergoing elective caesarean section.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients ≥ 18 years
- Singleton pregnancy
- Scheduled for elective caesarean section performed under spinal anaesthesia
- Written informed consent
You likely can't join if
- Allergy to or contraindications towards trial medication
- Patients planned for postoperative epidural due to expected difficult postoperative pain management
- Patients planned for combined spinal-epidural as primary anaesthesia
- Inability to understand and read Danish
- Previous inclusion in the trial
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.